Home » NEOPHARM PROVIDES LEP-ETU PROJECT UPDATE
NEOPHARM PROVIDES LEP-ETU PROJECT UPDATE
NeoPharm has announced that, based on the results of its recently completed bioequivalence study, the company's NeoLipid drug candidate LEP-ETU (Liposome Entrapped Paclitaxel "Easy to Use") has met the study criteria for demonstrating bioequivalence.
LEP-ETU is NeoPharm's liposomal formulation of paclitaxel (Taxol), which is a widely-used and approved treatment for advanced cancers, including ovarian, breast, and lung cancer. Based on this initial bioequivalence study, NeoPharm is accelerating the clinical program of LEP-ETU to support submission of a new drug application to the FDA.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May